News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
ViTToria Biotherapeutics Secures $15M
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Office of the Vice Provost for Research Provides Funding to 2023 Discovering the Future and Accelerating From Lab to Market Research Grant Recipients
The Office of the Vice Provost for Research has provided nearly $1 million in funding to support research through Discovering the Future and Accelerating From Lab to Market research grant programs.
Gov. Josh Shapiro, President Liz Magill, and others from the Penn community Celebrate the new Penn Institute for RNA Innovation
“One of our great strategic advantages is our compact and contiguous campus, where 12 amazing schools and a world-class health system coexist just a short walk from one another,” said Magill.
Vivodyne Awarded Multiple Patents and Closed a $38 Million Seed Funding Round
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
Mitchell Lab: Lipid nanoparticles that deliver mRNA to T cells show potential treatment for autoimmune diseases
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics’ Treats its First Canine Cancer Patient
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
IND Clearance Achieved by Cabaletta Bio
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
PCI Hosts IvyTech 2023
The goal was to discuss various topics related to technology commercialization, startup company formation, and building relationships between academia and the commercial sector.